Evidence map›Paper›PMID 33307106›Full record

ArticleToxicology2021

Analysis of reproducibility and robustness of a human microfluidic four-cell liver acinus microphysiology system (LAMPS).

Courtney Sakolish, Celeste E Reese, Yu-Syuan Luo, Alan Valdiviezo, Mark E Schurdak, Albert Gough, D Lansing Taylor, Weihsueh A Chiu, Lawrence A Vernetti, Ivan Rusyn

Open access · greenAbstract read
In one paragraph

Article in Toxicology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Cell reprogramming: methods, mechanisms and applications.Cell regeneration (London, England) · 2025
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Courtney SakolishDepartment of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX 77843, USA.
Celeste E ReeseDrug Discovery Institute and Department of Computational & Systems Biology, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Yu-Syuan LuoDepartment of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX 77843, USA.
Alan ValdiviezoDepartment of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX 77843, USA.
Mark E SchurdakDrug Discovery Institute and Department of Computational & Systems Biology, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Albert GoughDrug Discovery Institute and Department of Computational & Systems Biology, University of Pittsburgh, Pittsburgh, PA 15260, USA.
D Lansing TaylorDrug Discovery Institute and Department of Computational & Systems Biology, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Weihsueh A ChiuDepartment of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX 77843, USA.
Lawrence A VernettiDrug Discovery Institute and Department of Computational & Systems Biology, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Ivan RusynDepartment of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX 77843, USA. Electronic address: irusyn@cvm.tamu.edu.
Texas A&M University · USUniversity of Pittsburgh · USDiscovery Institute · US

Funding

Single cell, multi-parametric high throughput platform to classify endocrine disruptor potential of mixturesP42ES027704 · NIEHS · TEXAS A&M UNIVERSITY · PI Efstratios Pistikopoulos · 2017 to 2026
$21.2M
Texas A&M Center for Environmental Health Research (TiCER)P30ES029067 · NIEHS · TEXAS A&M UNIVERSITY · PI Sakhila Banu · 2019 to 2026
$13.0M
Harnessing human brain and liver microphysiological systems for testing therapeutics for metastatic melanomaU01TR002383 · NCATS · VANDERBILT UNIVERSITY · PI MURPHY, WILLIAM L., TAYLOR, D. LANSING · 2018 to 2022
$7.6M
Human Microphysiology Systems Disease Model of Type 2 Diabetes Starting with Liver and pancreatic IsletsUH3DK119973 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TAYLOR, D. LANSING · 2020 to 2022
$6.7M
Measuring the Temporal-Spatial Responses of Dormancy and Drug Resistance in a Human Breast Cancer Metastatic Niche within a Liver-on-a-Chip Microphysiological PlatformUH3TR000503 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TAYLOR, D. LANSING · 2014 to 2016
$6.2M
University of Pittsburgh Microphysiology Systems Database CenterU24TR002632 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GOUGH, ALBERT H, SCHURDAK, MARK E · 2018 to 2022
$5.1M
TEX-VAL: Texas A&M Tissue Chip Validation CenterU24TR001950 · NCATS · TEXAS A&M UNIVERSITY · PI RUSYN, IVAN · 2016 to 2017
$4.2M
Regulatory Science in Environmental Health and ToxicologyT32ES026568 · NIEHS · TEXAS A&M UNIVERSITY · PI Weihsueh A Chiu, Natalie M Johnson · 2016 to 2026
$3.8M
TEX-VAL: Texas A&M Tissue Chip Validation ConsortiumU24TR002633 · NCATS · TEXAS A&M UNIVERSITY · PI RUSYN, IVAN, STEPHAN, CLIFFORD C · 2018 to 2019
$3.0M
University of Pittsburgh Tissue Chip Testing CenterU24TR001935 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SCHURDAK, MARK E · 2016 to 2017
$2.7M
Collaborations to Extend the Microphysiology Database for Multiple Organ Models,UH2TR000503 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TAYLOR, D. LANSING, YARMUSH, MARTIN L · 2012 to 2013
$2.3M
Human Microphysiology Systems Disease Model of Type 2 Diabetes Starting with Liver and pancreatic IsletsUG3DK119973 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TAYLOR, D. LANSING · 2018 to 2019
$2.3M
NCATS NIH HHS U01 TR002383NCATS NIH HHS U24 TR001935NCATS NIH HHS U24 TR001950NCATS NIH HHS U24 TR002632NCATS NIH HHS U24 TR002633NCATS NIH HHS UH2 TR000503NCATS NIH HHS UH3 TR000503NIDDK NIH HHS UG3 DK119973NIDDK NIH HHS UH3 DK119973NIEHS NIH HHS P30 ES029067NIEHS NIH HHS P42 ES027704NIEHS NIH HHS T32 ES026568NIH HHS S10 OD012269
6 · The paper itself

Abstract

A human microfluidic four-cell liver acinus microphysiology system (LAMPS), was evaluated for reproducibility and robustness as a model for drug pharmacokinetics and toxicology. The model was constructed using primary human hepatocytes or human induced pluripotent stem cell (iPSC)-derived hepatocytes and 3 human cell lines for the endothelial, Kupffer and stellate cells. The model was tested in two laboratories and demonstrated to be reproducible in terms of basal function of hepatocytes, Terfenadine metabolism, and effects of Tolcapone (88 μM), Troglitazone (150 μM), and caffeine (600 μM) over 9 days in culture. Additional experiments compared basal outputs of albumin, urea, lactate dehydrogenase (LDH) and tumor necrosis factor (TNF)α, as well as drug metabolism and toxicity in the LAMPS model, and in 2D cultures seeded with either primary hepatocytes or iPSC-hepatocytes. Further experiments to study the effects of Terfenadine (10 μM), Tolcapone (88 μM), Trovafloxacin (150 μM with or without 1 μg/mL lipopolysaccharide), Troglitazone (28 μM), Rosiglitazone (0.8 μM), Pioglitazone (3 μM), and caffeine (600 μM) were carried out over 10 days. We found that both primary human hepatocytes and iPSC-derived hepatocytes in 3D culture maintained excellent basal liver function and Terfenadine metabolism over 10 days compared the same cells in 2D cultures. In 2D, non-overlay monolayer cultures, both cell types lost hepatocyte phenotypes after 48 h. With respect to drug effects, both cell types demonstrated comparable and more human-relevant effects in LAMPS, as compared to 2D cultures. Overall, these studies show that LAMPS is a robust and reproducible in vitro liver model, comparable in performance when seeded with either primary human hepatocytes or iPSC-derived hepatocytes, and more physiologically and clinically relevant than 2D monolayer cultures.

Indexed as

Acinar CellsCell Culture TechniquesHepatocytesHistamine H1 Antagonists, Non-SedatingHumansLiverMicrofluidicsTerfenadineHistamine H1 Antagonists, Non-SedatingTerfenadineDrug toxicityHepatotoxicityIn vitro

Identifiers

PMID33307106
PMCPMC7785655
OpenAlexW3113138899

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.